(PODD) Insulet - Ratings and Ratios
Insulin Delivery Systems, Automated Insulin Delivery, Diabetes Management
PODD EPS (Earnings per Share)
PODD Revenue
Description: PODD Insulet
Insulet Corporation is a leading developer and manufacturer of innovative insulin delivery systems for individuals with insulin-dependent diabetes. The companys flagship product, Omnipod, has evolved into a comprehensive platform with advanced features such as automated insulin delivery and smartphone-controlled management. The Omnipod5 and Omnipod DASH systems have transformed the way patients manage their diabetes, offering a more streamlined and user-friendly experience.
From a business perspective, Insulet Corporation has diversified its revenue streams beyond its core diabetes management products. The companys partnership with Amgen to supply pods for the Neulasta Onpro kit, a delivery system designed to mitigate infection risks associated with intense chemotherapy, demonstrates its ability to leverage its technology and manufacturing capabilities to address other medical needs.
Key performance indicators (KPIs) that are crucial in evaluating Insulet Corporations success include revenue growth rate, customer acquisition costs, and patient retention rates. The companys ability to expand its customer base through various channels, including pharmacies and independent distributors, is vital to its growth. Additionally, metrics such as gross margin and operating expenses as a percentage of revenue provide insight into the companys operational efficiency and ability to maintain profitability.
Analyzing Insulet Corporations financial health, we can see that the company has a significant market capitalization, indicating a substantial presence in the healthcare equipment sector. Its price-to-earnings ratio suggests that investors have high expectations for the companys future growth. The return on equity (RoE) of 34.53% indicates that Insulet is generating strong profits from its shareholders equity, highlighting effective management and a competitive edge in the market.
PODD Stock Overview
| Market Cap in USD | 24,527m |
| Sub-Industry | Health Care Equipment |
| IPO / Inception | 2007-05-15 |
PODD Stock Ratings
| Growth Rating | 44.9% |
| Fundamental | 82.6% |
| Dividend Rating | - |
| Return 12m vs S&P 500 | 15.4% |
| Analyst Rating | 4.43 of 5 |
PODD Dividends
Currently no dividends paidPODD Growth Ratios
| Growth Correlation 3m | 65.3% |
| Growth Correlation 12m | 79.3% |
| Growth Correlation 5y | -8.6% |
| CAGR 5y | 8.86% |
| CAGR/Max DD 3y | 0.14 |
| CAGR/Mean DD 3y | 0.45 |
| Sharpe Ratio 12m | 0.52 |
| Alpha | 0.00 |
| Beta | 0.884 |
| Volatility | 37.83% |
| Current Volume | 1109k |
| Average Volume 20d | 517.3k |
| Stop Loss | 312.5 (-3%) |
| Signal | -0.93 |
Piotroski VR‑10 (Strict, 0-10) 9.0
| Net Income (236.1m TTM) > 0 and > 6% of Revenue (6% = 141.6m TTM) |
| FCFTA 0.11 (>2.0%) and ΔFCFTA 5.00pp (YES ≥ +1.0pp, WARN ≥ +0.5pp) |
| NWC/Revenue 52.85% (prev 66.49%; Δ -13.64pp) (YES ≤20% & Δ≤-1pp; WARN ≤25% & Δ≤0 oder ≤40% & Δ≤-3pp) |
| CFO/TA 0.15 (>3.0%) and CFO 506.5m > Net Income 236.1m (YES >=105%, WARN >=100%) |
| Net Debt (424.5m) to EBITDA (407.3m) ratio: 1.04 <= 3.0 (WARN <= 3.5) |
| Current Ratio 2.23 (target 1.5–3.0; WARN 1.2–<1.5 or >3.0–5.0; CFO/TA gate active) |
| Outstanding Shares last Quarter (70.6m) change vs 12m ago -4.28% (target <= -2.0% for YES) |
| Gross Margin 70.75% (prev 69.00%; Δ 1.75pp) >=18% & Δ>=+0.5pp (WARN >=15% & Δ>=0) |
| Asset Turnover 74.31% (prev 64.99%; Δ 9.32pp) >=50% & Δ>=+2pp (WARN >=35% & Δ>=0) |
| Interest Coverage Ratio 6.44 (EBITDA TTM 407.3m / Interest Expense TTM 49.8m) >= 6 (WARN >= 3) |
Altman Z'' 3.19
| (A) 0.36 = (Total Current Assets 2.26b - Total Current Liabilities 1.01b) / Total Assets 3.47b |
| (B) 0.03 = Retained Earnings (Balance) 98.2m / Total Assets 3.47b |
| (C) 0.10 = EBIT TTM 320.5m / Avg Total Assets 3.18b |
| (D) 0.06 = Book Value of Equity 114.6m / Total Liabilities 2.01b |
| Total Rating: 3.19 = (6.56 * A) + (3.26 * B) + (6.72 * C) + (1.05 * D) |
ValueRay F-Score (Strict, 0-100) 82.64
| 1. Piotroski 9.0pt = 4.0 |
| 2. FCF Yield 1.58% = 0.79 |
| 3. FCF Margin 16.64% = 4.16 |
| 4. Debt/Equity 0.97 = 2.05 |
| 5. Debt/Ebitda 3.48 = -2.29 |
| 6. ROIC - WACC (= 26.44)% = 12.50 |
| 7. RoE 18.43% = 1.54 |
| 8. Rev. Trend 96.60% = 7.25 |
| 9. EPS Trend 53.05% = 2.65 |
What is the price of PODD shares?
Over the past week, the price has changed by -4.56%, over one month by -0.26%, over three months by +5.86% and over the past year by +36.80%.
Is Insulet a good stock to buy?
Based on momentum, paid dividends and discounted-cash-flow analyses, the fair value of PODD is around 311.17 USD . This means that PODD is currently overvalued and has a potential downside of -3.43%.
Is PODD a buy, sell or hold?
- Strong Buy: 14
- Buy: 6
- Hold: 2
- Sell: 1
- Strong Sell: 0
What are the forecasts/targets for the PODD price?
| Issuer | Target | Up/Down from current |
|---|---|---|
| Wallstreet Target Price | 353.4 | 9.7% |
| Analysts Target Price | 353.4 | 9.7% |
| ValueRay Target Price | 349.4 | 8.4% |
Last update: 2025-09-06 05:03
PODD Fundamental Data Overview
CCE Cash And Equivalents = 1.12b USD (Cash And Short Term Investments, last quarter)
P/E Trailing = 105.2659
P/E Forward = 62.1118
P/S = 10.3949
P/B = 16.6785
P/EG = 3.756
Beta = 1.366
Revenue TTM = 2.36b USD
EBIT TTM = 320.5m USD
EBITDA TTM = 407.3m USD
Long Term Debt = 939.0m USD (from longTermDebt, last quarter)
Short Term Debt = 478.4m USD (from shortTermDebt, last quarter)
Debt = 1.42b USD (Calculated: Short Term 478.4m + Long Term 939.0m)
Net Debt = 424.5m USD (from netDebt column, last quarter)
Enterprise Value = 24.82b USD (24.53b + Debt 1.42b - CCE 1.12b)
Interest Coverage Ratio = 6.44 (Ebit TTM 320.5m / Interest Expense TTM 49.8m)
FCF Yield = 1.58% (FCF TTM 392.6m / Enterprise Value 24.82b)
FCF Margin = 16.64% (FCF TTM 392.6m / Revenue TTM 2.36b)
Net Margin = 10.01% (Net Income TTM 236.1m / Revenue TTM 2.36b)
Gross Margin = 70.75% ((Revenue TTM 2.36b - Cost of Revenue TTM 690.2m) / Revenue TTM)
Tobins Q-Ratio = 216.6 (set to none) (Enterprise Value 24.82b / Book Value Of Equity 114.6m)
Interest Expense / Debt = 1.38% (Interest Expense 19.6m / Debt 1.42b)
Taxrate = -39.34% (set to none) (-118.1m / 300.2m)
NOPAT = unknown (EBIT/Op.Income or Taxrate missing)
Current Ratio = 2.23 (Total Current Assets 2.26b / Total Current Liabilities 1.01b)
Debt / Equity = 0.97 (Debt 1.42b / last Quarter total Stockholder Equity 1.46b)
Debt / EBITDA = 3.48 (Net Debt 424.5m / EBITDA 407.3m)
Debt / FCF = 3.61 (Debt 1.42b / FCF TTM 392.6m)
Total Stockholder Equity = 1.28b (last 4 quarters mean)
RoA = 6.81% (Net Income 236.1m, Total Assets 3.47b )
RoE = 18.43% (Net Income TTM 236.1m / Total Stockholder Equity 1.28b)
RoCE = 14.44% (Ebit 320.5m / (Equity 1.28b + L.T.Debt 939.0m))
RoIC = 26.44% (Ebit 320.5m / (Assets 3.47b - Current Assets 2.26b))
WACC = unknown (E(24.53b)/V(25.94b) * Re(9.27%)) + (D(1.42b)/V(25.94b) * Rd(1.38%) * (1-Tc(none)))
Shares Correlation 3-Years: 69.70 | Cagr: 0.16%
Discount Rate = 9.27% (= CAPM, Blume Beta Adj.)
[DCF Debug] Terminal Value 65.11% ; FCFE base≈308.4m ; Y1≈202.5m ; Y5≈92.6m
Fair Price DCF = 21.30 (DCF Value 1.50b / Shares Outstanding 70.4m; 5y FCF grow -40.0% → 3.0% )
EPS Correlation: 53.05 | EPS CAGR: -3.21% | SUE: -2.72 | # QB: 0
Revenue Correlation: 96.60 | Revenue CAGR: 26.40% | SUE: 3.42 | # QB: 2
Additional Sources for PODD Stock
Tweets: X | Stocktwits
Fund Manager Positions: Dataroma | Stockcircle